SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001725160-23-000029
Filing Date
2023-02-13
Accepted
2023-02-13 07:07:14
Documents
4
Period of Report
2023-02-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_167629002097801.html 3  
1 FORM 3 wf-form3_167629002097801.xml 3 1752
2 POWER OF ATTORNEY FOR IRIS ROTH HTML irispoaedgar.htm EX-24 5467
3 POWER OF ATTORNEY FOR IRIS ROTH GRAPHIC 1 irispoaedgar001.jpg GRAPHIC 243987
4 POWER OF ATTORNEY FOR IRIS ROTH GRAPHIC 2 irispoaedgar002.jpg GRAPHIC 110023
  Complete submission text file 0001725160-23-000029.txt   496641
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Roth Iris (Reporting) CIK: 0001964808 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 23614655